Open Study of the Clinical Effects of Lansoprazole in the Treatment of Reflux Oesophagitis
- 4 Downloads
The clinical efficacy and safety of lansoprazole, administered in a dose of 30mg once daily after breakfast, were studied in an open trial with 38 patients with erosive/ulcerative reflux oesophagitis. In 3 of these patients, the effect on gastro-oesophageal reflux and gastroduodenal motility was also investigated by 24-hour pH and motility monitoring, performed before and 1 week after starting lansoprazole therapy.
Lansoprazole almost completely reduced the total reflux (pH < 4) time and the number of reflux episodes lasting ⩾ 5 minutes, while it did not affect the induction of interdigestive migrating complex. The cumulative disappearance rate of overall subjective and objective symptoms was 66% after 1 week and 91% after 2 weeks. For individual symptoms the disappearance rate for heartburn was 79% after 1 week and 100% after 2 weeks of treatment. An endoscopic healing rate of 76% was achieved after 2 weeks, 97% after 4 weeks, and 97% after 8 weeks of lansoprazole treatment, and in poor responders to histamine H2-receptor antagonist therapy, the healing rate was 83% after 2 weeks and 100% after 4 weeks. Global improvement evaluation, as assessed by endoscopic findings and changes in symptoms and signs, showed ‘marked improvement’ in 94% and ‘moderate improvement’ in 6% of the patients.
In the overall safety evaluation, no problems occurred in 33 (86.8%) of the 38 patients. Three patients had mild cases of dry mouth. No serious abnormal changes in laboratory values were detected. Lansoprazole was deemed to be ‘extremely useful’ in 31 (89%) and ‘considerably useful’ in 3 (9%) of the 35 patients.
These results indicate that lansoprazole, administered in a dose of 30mg once daily after breakfast, inhibits gastro-oesophageal acid reflux almost completely, and it should prove to be a very useful therapeutic agent for reflux oesophagitis.
KeywordsOmeprazole Lansoprazole Famotidine Drug Invest Reflux Oesophagitis
Unable to display preview. Download preview PDF.
- Kishi S, Takemoto T, Tsuneoka K, Namiki M, Ishikawa M, et al. Evaluation of clinical usefulness of ranitidine on reflux esophagitis. Medical Consultation and New Remedies 19: 2978–2986, 1982Google Scholar
- Matsuo Y, Takemoto T, Miwa T, Iwasaki A, Asaoka A, et al. Clinical study of inhibitory effect of AG-1749, a proton pump inhibitor, on nocturnal gastric acid secretion-evaluation of dosage and administration stage. Japanese Pharmacology and Therapeutics 18: 4865–4876, 1990Google Scholar
- Nishioka T, Sekiguchi T, Kusano M, Matsuzaki T, Horikoshi T, et al. Effect of esophago-gastrointestinal prokinetic drug, H2-receptor antagonists and proton pump inhibitor on gastroesophageal reflux using 24-hour pH and motility monitoring method. Digestive Medicine 7: 374–380, 1987Google Scholar
- Nishioka T, Sekiguchi T, Ohwada T. Effect of secretin on gastrointestinal motor activity — a study on initiation of duodenal secretin-induced migrating motor complexes. Japanese Journal of Gastroenterology 77: 1879–1889, 1980Google Scholar
- Sekiguchi T, Horikoshi T. Twenty-four-hour pH and motility monitoring of esophagus stomach and duodenum. Clinical All-Round 39: 2290–2294, 1990Google Scholar
- Sekiguchi T, Nishioka T, Kogure M, Toki M, Horikoshi T, et al. Clinical evaluation of TZU-0460 on reflux esophagitis. Journal of New Remedies and Clinics 34: 1253–1258, 1985Google Scholar
- Sekiguchi T, Nishioka T, Kusano M, Matsuzaki T, Zennyoji K, et al. Clinical evaluation of omeprazole on reflux esophagitis. Japanese Pharmacology and Therapeutics 16 (Suppl. 2): 745–756, 1988Google Scholar
- Sekiguchi T, Nishioka T, Matsuzaki T, Kogure M, Toki M, et al. Clinical evaluation of cimetidine on reflux esophagitis. Japanese Pharmacology and Therapeutics 14: 7459–7466, 1986Google Scholar
- Sekiguchi T, Takasu Y, Miwa T, Kogure M, Nishioka T, et al. Clinical evaluation of famotidine on reflux esophagitis. Medical Consultation and New Remedies 20: 2476–2485, 1983Google Scholar
- Sekiguchi T, Tsuneoka K, Kobayashi M, Kogure T, Fukutomi H, et al. Clinical evaluation of nizatidine on reflux esophagitis. Japanese Pharmacology and Therapeutics 17 (Suppl. 2): 457–468, 1989Google Scholar
- Takemoto T, Namiki M, Gotoh Y, Matsuo Y, Miwa T, et al. Evaluation of clinical usefulness of lansoprazole (AG-1749) on gastric and duodenal ulcer — comparison with two dosages of lansoprazole and famotidine. Journal of Adult Disease 21: 743–767, 1991aGoogle Scholar
- Takemoto T, Namiki M, Gotoh Y, Matsuo Y, Miwa T, et al. Evaluation of clinical usefulness of lansoprazole (AG-1749) on gastric and duodenal ulcer — usefulness evaluation of lansoprazole 30 mg/day with famotidine as comparative drug. Journal of Adult Disease 21: 975–993, 1991bGoogle Scholar
- Takemoto T, Namiki M, Gotoh Y, Matsuo Y, Miwa T, et al. Evaluation of clinical usefulness of lansoprazole (AG 1749) on gastric and duodenal ulcer — evaluation of dosage and administration stage. Journal of Adult Disease 21: 995–1013, 1991cGoogle Scholar